Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 1925 of 2529 entries
View as:

Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases

Phase: N/A Priority: Normal
NCT ID: NCT00242554 Org: User:
Start: 10/31/02 End: - Due: -

A Phase I, Exploratory, Intra-patient Dose Escalation Study to Investigate the Preliminary Safety, Pharmacokinetics, and Anti-tumor Activity of Pasireotide (SOM230) s.c.Followed by Pasireotide LAR in Patients With Metastaticmelanoma or Metastatic Merkel Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT01652547 Org: User:
Start: 11/30/12 End: 04/30/15 Due: 04/30/16

Study of Oral AEE788 in Adults With Advanced Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00118456 Org: User:
Start: 07/31/03 End: - Due: -

Safety/Efficacy of Everolimus and Neoral® in Adult Cardiac Transplant Patients With Established Allograft Vasculopathy

Phase: N/A Priority: Normal
NCT ID: NCT00097968 Org: User:
Start: 08/31/04 End: - Due: -

Safety, Tolerability, and Efficacy of AIN457 in Patients With Uncontrolled Asthma

Phase: N/A Priority: Normal
NCT ID: NCT01478360 Org: User:
Start: 03/31/12 End: 11/30/14 Due: 11/30/15

To Evaluate Antiviral Efficacy of Telbivudine in Hepatitis B Antigen Positive (HbeAg-positive) Compensated Chronic Hepatitis B (CHB)

Phase: N/A Priority: Normal
NCT ID: NCT00537537 Org: User:
Start: 08/31/07 End: - Due: -

Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease

Phase: N/A Priority: Normal
NCT ID: NCT00690430 Org: User:
Start: 04/30/08 End: 04/30/12 Due: 04/30/13

Safety of RAD001 in Chinese Patients With Metastatic Renal Cell Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01152801 Org: User:
Start: 05/31/10 End: 12/31/13 Due: 12/31/14

Safety and Efficacy of Zoledronic Acid in Patients With Breast Cancer With Metastatic Bone Lesions

Phase: N/A Priority: Normal
NCT ID: NCT00375427 Org: User:
Start: 02/28/06 End: - Due: -

A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers.

Phase: N/A Priority: Normal
NCT ID: NCT02711345 Org: User:
Start: 04/15/16 End: 11/21/18 Due: 11/21/19

Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Itraconazole

Phase: N/A Priority: Normal
NCT ID: NCT05084651 Org: User:
Start: 11/18/21 End: 05/14/22 Due: 05/14/23

A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00600275 Org: User:
Start: 12/31/07 End: - Due: -

MAP to Provide Access to Crizanlizumab, for Sickle Cell Disease Patients

Phase: N/A Priority: Normal
NCT ID: NCT03720626 Org: User:
Start: - End: - Due: -

Safety, Tolerability and Abeta-specific Antibody Response of Repeated i.m. Injections of Adjuvanted CAD106 in Mild Alzheimer Patients

Phase: N/A Priority: Normal
NCT ID: NCT01097096 Org: User:
Start: 03/31/10 End: 12/31/12 Due: 12/31/13

24 Months Follow-up, Two Arm Study to Compare the Cardiovascular Profile in a Regimen With Everolimus + Mycophenolic Acid (MPA) Versus (vs.) a Regimen of CNI+MPA in Maintenance Renal Transplant Recipients

Phase: N/A Priority: Normal
NCT ID: NCT01169701 Org: User:
Start: 08/31/10 End: 03/31/14 Due: 03/31/15

Ruxolitinib for Polycythemia Vera in Patients Resistant to or Intolerant of Hydroxyurea.

Phase: N/A Priority: Normal
NCT ID: NCT05421104 Org: User:
Start: 11/27/20 End: 06/29/21 Due: 06/29/22

Extension Study of the Efficacy and Safety of Deferasirox Treatment in Beta-thalassemia Patients With Transfusional Hemosiderosis (Study Amended to 2-year Duration)

Phase: N/A Priority: Normal
NCT ID: NCT00171301 Org: User:
Start: 06/30/05 End: 05/31/08 Due: 05/31/09

12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients

Phase: N/A Priority: Normal
NCT ID: NCT01843348 Org: User:
Start: 12/27/12 End: 03/23/16 Due: 03/23/17

Pharmacokinetics Study of Ianalumab in Chinese Participants With Autoimmune Diseases

Phase: N/A Priority: Normal
NCT ID: NCT06411639 Org: User:
Start: 11/25/24 End: 06/24/28 Due: 06/24/29

Study of Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inclisiran in Chinese Participants With Elevated Serum LDL-C

Phase: N/A Priority: Normal
NCT ID: NCT04774003 Org: User:
Start: 02/26/21 End: 10/18/21 Due: 10/18/22

A Study to Assess the Safety and Efficacy of ECF843 vs Vehicle in Subjects With Dry Eye Disease

Phase: N/A Priority: Normal
NCT ID: NCT04391894 Org: User:
Start: 10/06/20 End: 05/13/21 Due: 05/13/22

Study of Efficacy and Safety of Secukinumab in Patients With Non-radiographic Axial Spondyloarthritis

Phase: N/A Priority: Normal
NCT ID: NCT02696031 Org: User:
Start: 04/29/16 End: 03/11/21 Due: 03/11/22

GSK1120212 Rollover Study

Phase: N/A Priority: Normal
NCT ID: NCT01376310 Org: User:
Start: 11/02/10 End: 01/18/18 Due: 01/18/19

Treatment of Patients Suffering From a Progressive Pancreas Carcinoma With Everolimus (RAD001) and Gemcitabine

Phase: N/A Priority: Normal
NCT ID: NCT00560963 Org: User:
Start: 10/31/07 End: 01/31/11 Due: 01/31/12

Special Drug Use-results Surveillance of Tabrecta Tablets

Phase: N/A Priority: Normal
NCT ID: NCT04575025 Org: User:
Start: 11/02/20 End: 10/26/24 Due: 10/26/25